Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
EBITDA Margin Over TimeStable
Percentile Rank64
3Y CAGR-2.1%
5Y CAGR-3.4%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
-2.1%/yr
vs +1.5%/yr prior
5Y CAGR
-3.4%/yr
Consistent
Acceleration
-3.6pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive growthStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 40.57% | +8.3% |
| 2024 | 37.45% | +4.7% |
| 2023 | 35.78% | -17.2% |
| 2022 | 43.21% | -28.2% |
| 2021 | 60.16% | +24.6% |
| 2020 | 48.29% | +18.6% |
| 2019 | 40.71% | +0.1% |
| 2018 | 40.68% | +6.2% |
| 2017 | 38.30% | +29.1% |
| 2016 | 29.66% | - |